Item 8.01. Other Events. On October 21, 2021, Selecta Biosciences, Inc. (the "Company") entered into an Exclusive License Agreement (the "Agreement") with Genovis AB (publ.), a Swedish corporation ("Genovis"). Under the Agreement, the Company paid to Genovis an upfront payment in exchange for an exclusive license to Genovis' Xork IgG Protease enzyme technology across all therapeutic uses in humans, excluding research, preclinical, diagnostic and other potential non-therapeutic applications of the enzyme. Additionally, Genovis is eligible to earn development and sales-based milestones, as well as tiered royalties on worldwide sales in the low double digits.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses